Paxlovid™ untuk Pasien COVID-19 Dewasa Berisiko Tinggi yang Dirawat Jalan - Telaah Jurnal Alomedika

Oleh :
dr.Eduward Thendiono, SpPD,FINASIM

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine. 2022 Feb 16. PMID: 35172054.

Abstrak

Latar belakang: Paxlovid™ (nirmatrelvir 300 mg dan ritonavir 100 mg) merupakan main protease inhibitor (Mpro) oral terhadap severe acute respiratory syndrome coronavirus 2, yang memiliki aktivitas poten pan-human-coronavirus in vitro.

Referensi